.svg){kind=small}
Jun-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Market Insights Snapshot
In June 2026, 1906’s mix concentrated further into Capsules at 95.77% share, while Edible held 4.16% and the residual long tail in Concentrates and Pre-Roll combined for just 0.07%. Capsules declined 47.21% year over year and 10.01% month over month, yet the pullback was steeper in Edible at 67.74% YoY and 27.56% MoM, and acute in Concentrates at 56.15% YoY and 76.58% MoM. Average price rose 3.59% YoY to $20.85 while Capsules averaged $20.72, indicating mix-down within the premium range as total brand sales fell 48.58% YoY and 63.19% over 24 months. The pattern implies 1906 is consolidating around Capsules volume while letting peripheral categories contract, trading breadth for depth in a way that preserves category leadership potential despite shrinking totals.
With Capsules ranking 1 in Illinois and commanding 95.77% of brand sales, the category dependence raises concentration risk if the 10.01% MoM slide persists alongside a 47.21% YoY decline. The sharper MoM contractions in Edible (27.56%) and Concentrates (76.58%) indicate these are no longer meaningful hedges; combined sub-5% share limits cross-category insulation as pricing nudges up 3.59% YoY. This mix trajectory implies 1906’s positioning hinges on defending first-place Capsules velocity and price-pack architecture, because recovery now relies more on stabilizing a single category than on multi-category re-expansion.
Competitive Landscape
1906 holds #1 in NY Capsules in June 2026, unchanged from #1 a year earlier, and steady at #1 over the last three months; this stability contrasts with Level sitting at #2 with a -16.1% year-over-year sales change and Canna Clinicals slipping from #3 to #5 alongside a -41.1% decline, while 1906 hit its peak rank of #1 in June 2026 and maintained the top spot from June 2025 to June 2026. With Revival at #3 and Grassroots at #4, the lack of upward movement from #2–#4 competitors and the negative sales trend at #2 and #5 imply that 1906’s unbroken #1 rank is being reinforced by rival retrenchment rather than by category-wide expansion.
Notable Products
Boost Plus Pouch Tablets 3-Pack (90mg) posted the steepest decline at -36.8% month over month and slid to rank 8, while CBD/THC 1:1 Love Drops 30-Pack (75mg CBD, 75mg THC) fell -29.9% to rank 7; in contrast, Boost Drops Pills 20-Pack (100mg) inched up +4.2% to hold rank 2. With the top three ranks all in Capsules and nine of the top ten SKUs also in Capsules, the category concentration is pronounced, yet leadership skews to 1:1 and CBD-forward ratios as CBD/THC 1:1 Bliss Tablets 20-Pack (100mg CBD, 100mg THC) remains rank 1 despite a -5.9% dip.
The split between modest gains at the core and double‑digit pullbacks in smaller pouches and 30-packs implies 1906 is consolidating demand into flagship 20-pack formats, signaling a need to streamline SKUs toward higher-velocity ratios rather than proliferating package sizes.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
